Nanomedical system for nucleic acid drugs created with the biodegradable nanoparticle platform.
Nanomedical applications of biodegradable poly(DL-lactide-co-glycolide) (PLGA) nanoparticles (NPs) developed are discussed in this review. A surface-functionalized PLGA NP platform for drug delivery was established to encapsulate a number of macromolecular drugs such as peptides and nucleic acids as well as low-molecular-weight drugs by the emulsion solvent diffusion method. The interaction of PLGA NPs with cells and tissues could be controlled by changing the surface properties of NPs, suggesting their potential utility for the intracellular drug delivery of nucleic acid-based drugs. Furthermore, orally administered NF-κB decoy oligonucleotide-loaded CS-PLGA NPs are also useful in treating experimental colitis. These approaches using surface-modified PLGA NPs could be able to open new possibilities for nucleic acid-based drug delivery via noninvasive administration method.
Laboratory of Pharmaceutical Engineering, School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto, Chikusa, Nagoya, Japan.
Hiromitsu
H
Yamamoto
Kohei
K
Tahara
Yoshiaki
Y
Kawashima
D000284:Administration, Oral; D001672:Biocompatible Materials; D004058:Diffusion; D004655:Emulsions; D019344:Lactic Acid / Q000737:chemistry; D053758:Nanoparticles; D009696:Nucleic Acids / Q000737:chemistry / Q000494:pharmacology*; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012997:Solvents; D013499:Surface Properties
D001672:Biocompatible Materials; D004655:Emulsions; D009696:Nucleic Acids; D012997:Solvents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid